Division News

Thomas Holland, MD, medical instructor in the Division of Infectious Diseases and hospitalist at Duke University Hospital, coauthored a JAMA review of evidence of management strategies for S aureus bacteremia to determine whether transesophageal echocardiography is necessary in all adult cases and what is the optimal antibiotic therapy for methicillin-resistant S aureus (MRSA) bacteremia. Read the review article.

Thomas Holland, MD, medical instructor in the Division of Infectious Diseases and hospitalist at Duke University Hospital, coauthored a JAMA review of evidence of management strategies for S aureus bacteremia to determine whether transesophageal echocardiography is necessary in all adult cases and what is the optimal antibiotic therapy for methicillin-resistant S aureus (MRSA) bacteremia. Read the review article.

The Antibiotic Resistance Leadership Group (ARLG), based at Duke as part of a six-year, $62 million federal grant to Vance Fowler, MD, MHS, and a group of researchers at Duke and across the country (learn more), is mentioned as an important part of a new ex

The Antibiotic Resistance Leadership Group (ARLG), based at Duke as part of a six-year, $62 million federal grant to Vance Fowler, MD, MHS, and a group of researchers at Duke and across the country (learn more), is mentioned as an important part of a new ex

Joshua Thaden, MD, fellow in the Division of Infectious Diseases, was interviewed on the NPR show Here and Now about his recent research in Carbapenem-resistant enterobacteriaceae (CRE).

Gregory Gray, MD, MPH, an expert in influenza and a proponent of interdisciplinary approaches to problem solving in health care, has joined the Division of Infectious Diseases as professor of medicine. Dr.

Don't forget: Tomorrow's Medicine Grand Rounds will feature two special presentations. Medicine Grand Rounds on Fri., June 27 at 8 a.m. in Duke Hospital room 2002 will feature Mary E. Klotman, MD, chair of the Department of Medicine and R.J.

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers. Researchers said the advantage of the new drug, oritavancin, is its potential to curtail what has been a key driver of antibiotic resistance: a tendency for patients to stop taking antibiotics once they feel better.

[caption id="attachment_15540" align="alignright" width="300"] The circle plot displays how the same genetic differences can contribute to multiple human traits and diseases.

Medicine Grand Rounds on Fri., May 23 at 8 a.m. in Duke Hospital room 2002 will feature Aimee Zaas, MD, MHS, associate professor of medicine (Infectious Diseases) and Program Director, Internal Medicine Residency Program. Dr.